ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.
Pharmacology, Toxicology and Pharmaceutical Science
2
11%
Environmental Science
1
6%
Biochemistry, Genetics and Molecular Biology
1
6%
Business, Management and Accounting
1
6%
Other
0
0%
Unknown
7
39%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2022.
All research outputs
#2,313,667
of 23,330,477 outputs
Outputs from Journal of Clinical Oncology
#5,381
of 20,294 outputs
Outputs of similar age
#51,757
of 445,365 outputs
Outputs of similar age from Journal of Clinical Oncology
#208
of 829 outputs
Altmetric has tracked 23,330,477 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,294 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.8. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,365 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 829 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
